The War on Cancer

Townsend Letter for Doctors and Patients,  Oct, 2001  by Ralph W. Moss

• E-mail
• Print
• Link

An Innovative Cancer Course in Philadelphia

In November, I will help teach a course on complementary and alternative approaches to cancer at the Center for Integrative Medicine (CIM) in Philadelphia. The CIM is part of Thomas Jefferson University Hospital and Thomas Jefferson University. The course will begin after lunch on Friday, November 16, and then proceed all day on Saturday, November 17, 2001. We hope to enlist the help of Philadelphia oncologists and other medical specialists to make this innovative course a big success. We have also applied for Continuing Education credit for attendees.

At this writing, the course is still in the planning phase. But during these two days, we intend to intensively cover many topics of great interest to medical professionals who are interested in the CAM treatment of cancer. Some of the likely topics are: an overview of the field, and of the involvement of the NIH and NCI in CAM research; the use of popular supplements such as antioxidants and their interaction with chemotherapy; a discussion of mistletoe, and other botanicals and immune modulators in cancer treatment; the use of anti-angiogenic agents in the CAM context; breast cancer and soy isoflavones; polysaccharides and medicinal mushrooms; hyperthermia as a "fourth modality" of cancer treatment; PC SPES and other new treatments for prostate cancer; and some of the psychological and spiritual dimensions of cancer care. For details on registration please contact Sharifa Pettigrew at the Center for Integrative Medicine at Thomas Jefferson University Hospital 215-503-0720 or email sharifa.pettigrew@mail.tj u.edu

The Marienlyst Conference

This summer I had the pleasure of attending the Seventh International Symposium for Biologically Closed Electric Circuits in Biomedicine. This important meeting was held at the Marienlyst Conference Center in Helsingor (Elsinore), a city north of Copenhagen best known as the setting of Shakespeare's Hamlet.

The meeting was sponsored by the International Association for Biologically Closed Electric Circuits in Biomedicine (IABC). The local sponsor was Finn Scott Andersen, MD, medical director of the nearby Humlegaarden cancer clinic. My wife and I stayed at Humlegaarden for eight days and so got a better understanding of the workings of this unique healing community. The inquisitive spirit of Finn Andersen shaped every aspect of the conference, especially the lively and open-minded atmosphere regarding all new cancer treatments.

The IABC promotes the use of harmless low-level electrical currents and magnetic fields in the treatment of cancer, neurological disorders, and other diseases. The group had an unusual genesis. Although the current leadership is mainly American (Prof. George O'Clock, PhD of Minnesota State and Carl F. Firley, BS) the association originated with the Swedish scientist, Bjorn E.W. Nordenstrom, MD, and his Chinese colleagnes. Dr. Nordenstrom is the inventor of the skinny needle biopsy used all over the world to diagnose cancer; he was also one of the pioneers of balloon catheterization for heart disease. At one time, he chaired the Nobel Prize committee that awarded the biology/medicine award.

In the 1970s, he began to experiment with the effects of low level electrical currents on the human body and published a scholarly book on the subject. He developed a new approach to treating cancer which is known today as electrochemical therapy, or ECHT. His clinical results in Sweden were remarkable. In November, 1980 New York magazine published a a three-part, front-page series on his work. What followed, however, was not universal acclaim but the unreasonable rejection of his ideas by various orthodox medical authorities.

Undeterred, Prof. Nordenstrom took his treatment to the People's Republic of China, which is more open to innovative approaches. Professor Xin Yu-Ling, director of thoracic surgery at the China-Japan Friendship Hospital, Beijing, welcomed the chance to work with this world-famous scientist. Their collaboration began in Beijing in 1987 and the IABC was then formed {Eur J Surg Suppl 1994;574:7-23}. Under the direction of Prof. Xin, more than 10,000 cancer patients were treated {Eur J Surg Suppl. 1994;574:25-29}. The treatment is now fully accepted by the Chinese Medical Association and there are more than 300 Chinese members of the IABC. About two dozen of these colleagues attended the meeting in Helsingor. In addition, there are about 200 associates in Europe and another 100 in the US and South America. (For more information about joining this important organization readers should contact Carl Firley at iabc.adelphia.net).

There were also participants from South Korea, where ECHT has recently been introduced into an 800-bed hospital and from Alexandroupolis, Greece, where the treatment of neurological disorders using ECHT is well underway. Members from about a dozen other countries were also represented at the conference. So "international" in the title is more than wishful thinking.